

PR#: 14343 Deviation No.:D-2021-0239

Record Status: Deviation Investigation in Progress

基本信息 General Information

厂区 Division: Innovent Biologics (Su Zhou) Co., Ltd

发起人 Originator: 刘, 晶晶(PID-000080) 发起日期 Date Opened: 2021.05.14

简短描述 Short Description:

M1b DS1 IBI308 2nd VF收集液蛋白检测数据丢失 Protein detection data of IBI308 2nd VF pool was lost

到期日期 Date Due: 2021.06.18 关闭日期 Date Closed:

偏差信息 Deviation Information

发现人 Discovery By:刘晶晶20000454发现日期 Discovery On:2021.05.12汇报人Report By:刘晶晶20000454汇报日期 Report On:2021.05.12

发生部门 Occurred Department: M1b DS1 汇报部门 Report Department: M1b DS1

偏差描述 Deviation Description:

2021.05.12 21:32 纯化人员(20000454)在进行VF蛋白检测读取a1、a2、b1、b2紫外数据过程中,读取到b1数据时,发现b1数据将a2数据覆盖。上报QA、MST、上级,讨论后保存当前图谱文件,后续联系AIS审核历史数据,确认数据是否丢失。于2021.05.13 15:24 AIS及生产人员针对该时间段进行历史数据审核后,发现纯化操作人员实际读取三次数据,但是图谱中只保存了a1和b1两个数据,a2数据缺失(见附件1),故发起偏差对改事件进行调查。

描述的附件 Description attachment: 附件1 异常蛋白检测图谱及记录.docx

是否及时上报? Reporting in Time?: Yes

未及时上报的理由 Reason for not in Time:

2021.05.12 21:32异常事件发生后,上报现场QA、MST、上级,讨论后于2021.05.13由AIS审核历史记录,查看被覆盖数据是否仍然存在;2021.05.13 15:24AIS人员查看历史记录后,发现a2数据丢失,生产人员于2021.05.13 17:27针对该数据丢失,已线下上报现场QA。

已采取的即时措施 Immediately Action Taken:

05/14/2021 04:22 PM (GMT+8:00) added by 晶晶 刘 (PID-000080):

- 1、保存当前图谱文件(见附件1)/MFG/2021.05.12
- 2、重启电脑及紫外分光光度计后,重新进行系统适应性检测(见附件2),重新进行蛋白浓

度检测(见附件3)。MFG/2021.05.12

即时措施附件 Immediately Action Attachment:

附件2 重启设备后适应性检测图谱.pdf

附件3设备重启后VF蛋白浓度检测图谱.pdf

厂房设施名称 Facility Name: 产品所属阶段 Product Phase:

M1b Clinical

初步影响/风险评估Initial Impact/Risk Assessment

产品影响评估 Product Impact Assessment:

本偏差影响到VF收集液的蛋白检测,不涉及工艺和生产操作的偏离,同时设备重启后,系统适应性和蛋白检测正常,因此对产品质量无影响。

生产/检测的影响评估 Production/Testing Impact Assessment:

紫外分光光度计:设备编号为MFG-M1b2-132,设备的计量有效期至2022.04.26,设备的PM有效期至2021.05.15(缓冲期60天),设备处于正常状态。根据即时措施判断,偏差发生后,重启设备后可正常使用,且设备从2019.07投产至偏差发生期间,未发生类似情况。评估得出设备再次发生故障的可能性较低,且异常能够立即识别,考虑到该区域只有一台紫外分光光度计,如果使用其他房间的设备进行蛋白检测,可能存在交叉污染的风险,因此可继续使用该设备用于蛋白检测,同时为防止检测过程再次发生数据被覆盖的情况,要求生产人员进行蛋白检测过程,读取的每一个数据都需截图保存。用于后续偏差调查评估使用。



PR#: 14343 Deviation No.:D-2021-0239

Record Status: Deviation Investigation in Progress

其他影响评估描述 Other Impact Assessment Description:

生产人员在进行VF收集液蛋白检测依次读取a1、a2、b1、b2 UV280检测数据过程中,读取b1数据时,发现b1数据将a2数据覆盖,导致a2数据丢失。根据审计追踪,确认操作人员检测了a1、a2、b1,但是打开保存的结果文件,确认只有a1和b1的数据,因此该偏差对VF蛋白检测的数据完整性产生影响,需要对该偏差调查。

初步影响评估附件 Initial Impact Assessment Attachment:

偏差分级 Deviation Classification

偏差严重性 Deviation Severity:

对产品SISPQ的影响:

本偏差影响到VF收集液的蛋白检测,不涉及工艺和生产操作的偏离,同时设备重启后,系统适应性和蛋白检测正常,因此对产品质量无影响。

但是该偏差存在产品批次生产数据的丢失,可能存在数据可靠性的问题,需要进一步调查分析。

偏差发生率 Reoccurrence Probability of Deviation:

过去12个月该区域同类型缺陷回顾(关键词搜索: M1b DS1、IBI308 2nd、VF收集液蛋白检测、数据丢失)

未发现同类型缺陷。

偏差分级 Deviation Classification: Major

分级的理由 Reason for Classification:

05/17/2021 07:04 PM (GMT+8:00) added by 育芳 刘 (PID-000093):

该偏差还需进一步分析根本原因,根据根本原因考虑建立CAPA措施。

综上,该偏差定义为主要偏差。

是否需要调查? Investigation Required?: Yes

主调查人 Lead investigator: 邱, 明

不需要调查的理由 Reason for not Investigation:

调查总结&根本原因分析 Investigation & RCA

调查总结 Investigation Summary:

调查附件 Investigation Attachments:

根本原因分析 Root Cause Analysis:

根本原因分析附件 Root Cause Analysis Attachment:

原因描述 Cause Description:

原因分类 Cause Category 原因子分类 Cause Sub-Category 原因归属部门 Cause Department



PR#: 14343 Deviation No.:D-2021-0239

Record Status: Deviation Investigation in Progress

缺陷描述 Defect Description:

2021.05.12 21:32 纯化人员在进行VF蛋白检测读取a1、a2、b1、b2紫外数据过程中,读取到b1数据时,发现b1数据将a2数据覆盖。上报QA、MST、上级,讨论后保存当前图谱文件,后续联系AIS审核历史数据,确认数据是否丢失。于2021.05.13 15:24 AIS及生产人员针对该时间段进行历史数据审核后,发现纯化操作人员实际读取三次数据,但是图谱中只保存了a1和b1两个数据,a2数据缺失,故发起偏差对改事件进行调查。

缺陷类型分类 Defect Category

缺陷类型子分类 Defect Sub-Category

Production/Process Operation

見	否是	雷复	偏差	Repeat	Dev	iatio	n? ·
ᄮ	ᅳᄹ	生女	川上	Nepeat	$\nu \epsilon_{\nu}$	iatioi	1: .

判定重复偏差的原因 Justification for Repeat Deviation

判定重复偏差的原因 Justification for Repeat Deviation:					
重复偏差的原因描	述 Reason of Repeat Deviation	n Description:			
相关的重复偏差 F PR#	Repeat Deviation Records deviation#	简短描述 Short Description	Record Status		
最终影响/风险评	古 Final Impact/Risk Assessm	ent			
对产品质量的影响	Impact on Product Quality:				
对其他批次的影响	Impact on Other Batches:				
对系统/设备的影响	向 Impact on System/Equipmer	nt:			
对验证状态的影响	Impact on Validation State:				
对产品注册的影响	Impact on Product Registration	on:			
对法规符合性的影	响 Impact on Regulation Com	pliance:			
对稳定性的影响 Impact on Stability:					

对其他方面的影响 Impact on Other Aspects:

受影响的部门 Impact Departments:

影响/风险评估附件 Impact/Risk Assessment Attachment:



PR#: 14343 Deviation No.:D-2021-0239

Record Status: Deviation Investigation in Progress

受影响的产品信息 Impacted Product Information

产品最终处置建议 Product Disposition Proposal:

产品名称 Product Name: 信迪利单抗注射液M1b 3000L原液 (二代细胞株)

产品代码 Product Code 产品批号 Batch No.: 数量 Quantity 处理决定 Disposition

DS01-308B-2 DS2103014 3000L

受影响的物料信息 Impacted Material Information

物料名称 Material Name:

受影响的溶液信息 Impacted Media/Buffer Information

溶液名称 Media/Buffer Name:

受影响的设备信息 Impacted Equipment Information

设备名称 Equipment Name: 设备代码 Equipment Code

偏差处理措施 Deviation Action Items

PR#:

责任人 Assigned To: 部门 Department:

截止日期 Date Due: 完成日期 Completed Date:

确认人 Verified By: 确认日期 Verified On:

行动项详细描述 Action Description:

纠正信息 Correction Information

PR#:

截止日期 Date Due: 完成日期 Completed Date:

确认人 Verified By: 确认日期 Verified On:



PR#: 14343	Deviation No.:D-2021-023
------------	--------------------------

Record Status: Deviation Investigation in Progress

行动项详细描述	Action	Description:
	ACTION	Description.

纠正与预防措施 CAPA

PR#:

责任人 Assigned To:

部门 Department:

截止日期 Date Due:

行动项详细描述 Action Description:

附件 File Attachments

关联记录 Reference Records

PR# Record Type 简短描述 Short Description Record Status

相关子记录 Related children

PR# Record Type 简短描述 Short Description Record Status



Deviation No.:D-2021-0239 PR#: 14343

Record Status: Deviation Investigation	in Progress		
Initial Approval			
QA Initial Review			
Area QA Initial Reviewed By:	吴, 烜	Area QA Initial Reviewed On:	2021.05.14 18:05
Classify Completed By:	刘, 育芳	Classify Completed On:	2021.05.17 19:06
Department Initial Review			
Department Leader 1 Reviewed By:	康, 云	Department Leader 1 Reviewed On:	2021.05.17 20:51
Department Leader 2 Reviewed By:		Department Leader 2 Reviewed On:	
Department Leader 3 Reviewed By:		Department Leader 3 Reviewed On:	
Department Leader 4 Reviewed By:		Department Leader 4 Reviewed On:	
Department Leader 5 Reviewed By:		Department Leader 5 Reviewed On:	
Area QA Leader Reviewed By:	代, 圆圆	Area QA Leader Reviewed On:	2021.05.18 10:56
Quality Initial Approval			
Quality Approver 1 Approved By:	管, 国兴	Quality Approver 1 Approved On:	2021.05.18 11:04
Quality Approver 2 Approved By:		Quality Approver 2 Approved On:	
Quality Approver 3 Approved By:		Quality Approver 3 Approved On:	
Final Approval			
QA Final Review			
QA Final Reviewed By:		QA Final Reviewed On:	
Investigator Final Review			
Investigator Final Review QA Representative Reviewed By:		QA Representative Reviewed On:	
		QA Representative Reviewed On: Investigator 1 Reviewed On:	
QA Representative Reviewed By:		·	
QA Representative Reviewed By: Investigator 1 Reviewed By:		Investigator 1 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By:	By:	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On:	On:
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By:		Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On:	
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval	By:	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On:	n:
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By:	8y: 8y:	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Department Leader 1 Final Approved On: Department Leader 2 Final Approved On:	0n: 0n:
QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval Department Leader 1 Final Approved By: Department Leader 2 Final Approved By: Department Leader 3 Final Approved By:	By: By:	Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Department Leader 1 Final Approved On: Department Leader 2 Final Approved On: Department Leader 3 Final Approved On: Department Leader 3 Final Approved On: Department Leader 3 Final Approved On:	on: On: On:

This report was generated by 鹏云 徐 on 2021.06.17 04:49PM in Timezone GMT+08:00

Quality Approver 1 Final Approved By:

Quality Approver 2 Final Approved By:

Quality Approver 1 Final Approved On: Quality Approver 2 Final Approved On:



PR#: 14343 Deviation No.:D-2021-0239

Record Status: Deviation Investigation in Progress

Quality Approver 3 Final Approved By: Quality Approver 3 Final Approved On:

Product Final Disposition

Disposition Proposed By:

Proposal Reviewed By:

Disposition Proposed On:

Proposal Reviewed On:

Product Disposition Approved By: Product Disposition Approved On: